Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole
Completed
University of Pisa
N/A
2014-01-01
Evaluation of the efficacy of the combined treatment (methimazole plus selenium) in the
control of hyperthyroidism as compared to methimazole alone in 30 Graves' disease (GD)
untreated patients.
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Not yet recruiting
Emory University
Early Phase 1
2021-12-31
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic
state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial
aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is
safe and could benefit cancer treatment.
A Phase 2 Study of Methimazole in Patients With Progressive Glioblastoma
Not yet recruiting
Case Comprehensive Cancer Center
Phase 2
2024-01-01
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug
called Methimazole. The investigational drug, Methimazole is not FDA approved for brain
tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be
given to several study participants with glioblastoma. The first several study participants
will receive the lowest dose. If the drug does not cause serious side effects, it will be
given to other study participants at a higher dose. The doses will continue to increase for
every group of study participants until the side effects occur that require the dose to be
lowered. The procedures in this study are research blood draws, physical exams, collection of
medical history, MRI scans, and study drug administration.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
